Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
iRobot Files for Chapter 11 Bankruptcy Amid Rising Competition and Tariff Pressures 
MetaX IPO Soars as China’s AI Chip Stocks Ignite Investor Frenzy 
Apple Explores India for iPhone Chip Assembly as Manufacturing Push Accelerates 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
Biren Technology Targets Hong Kong IPO to Raise $300 Million Amid China’s AI Chip Push 
Shell M&A Chief Exits After BP Takeover Proposal Rejected 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track 
Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness 
EU Signals Major Shift on 2035 Combustion Engine Ban Amid Auto Industry Pressure 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
Amazon in Talks to Invest $10 Billion in OpenAI as AI Firm Eyes $1 Trillion IPO Valuation 
FAA Unveils Flight Plan 2026 to Strengthen Aviation Safety and Workforce Development 
Ford Takes $19.5 Billion Charge as EV Strategy Shifts Toward Hybrids 
MENLO PARK, Calif., Jan. 19, 2016 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ:PACB) will hold its quarterly conference call to discuss its Fourth Quarter and Year End 2015 Financial Results on Tuesday, February 2, 2016, at 4:30pm Eastern Time.
The call will be webcast and may be accessed at Pacific Biosciences’ website at: http://investor.pacificbiosciences.com/.
Date: February 2, 2016
Time: 4:30pm ET
Listen via Internet: http://investor.pacificbiosciences.com/
Toll-free: 888.366.7247
International: 707.287.9330
Replay: http://investor.pacificbiosciences.com
About Pacific Biosciences
Pacific Biosciences of California, Inc. (NASDAQ:PACB) offers sequencing systems to help scientists resolve genetically complex problems. Based on its novel Single Molecule, Real-Time (SMRT®) technology, Pacific Biosciences' products enable: de novo genome assembly to finish genomes in order to more fully identify, annotate and decipher genomic structures; full-length transcript analysis to improve annotations in reference genomes, characterize alternatively spliced isoforms in important gene families, and find novel genes; targeted sequencing to more comprehensively characterize genetic variations; and DNA base modification identification to help characterize epigenetic regulation and DNA damage. Pacific Biosciences' technology provides the industry's highest consensus accuracy over the longest read lengths in combination with the ability to detect real-time kinetic information. PacBio sequencing systems, including consumables and software, provide a simple, fast, end-to-end workflow for SMRT Sequencing. More information is available at www.pacb.com.
Contact: Pacific Biosciences Trevin Rard 650.521.8450 [email protected]
